Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma.
Pancreatic ductal adenocarcinoma (PDAC) accounts for over 213 000 deaths worldwide each year, largely due to late diagnosis. One of the risk factors for the development of PDAC is chronic pancreatitis (CP); the intense desmoplastic reaction makes differentiation between the two conditions extremely difficult. In order to identify biomarkers for noninvasive diagnosis, we performed 2-D DIGE analysis of urine samples from healthy individuals and patients with PDAC and CP. Despite considerable intersample heterogeneity, a total of 127 statistically valid (p<0.05), differentially expressed protein spots were detected, 101 of which were identified using MALDI-TOF MS. A number of these, including annexin A2, gelsolin and CD59 have already been associated with PDAC, however, their validation using immunoblotting proved challenging. This is probably due to extensive PTMs and processing thus indicating the need for raising specific antibodies for urinary proteins. Despite this, our study clearly demonstrates that urine is a valid source of noninvasive biomarkers in patients with pancreatic diseases.
Institute of Cancer, Barts and The London, Queen Mary's School of Medicine and Dentistry, London, UK.
Mark E
ME
Weeks
Deepak
D
Hariharan
Ljiljana
L
Petronijevic
Tomasz P
TP
Radon
Hannah J
HJ
Whiteman
Hemant M
HM
Kocher
John F
JF
Timms
Nicholas R
NR
Lemoine
Tatjana
T
Crnogorac-Jurcevic